

## Ludger Glycoprofiling Services: N-Glycan Site Occupancy Analysis

The amino acid sequence of the glycoprotein determines the number of potential N-glycosylation sites. As shown in the workflow below, the relative proportion of occupied N-glycan sites can be determined using a PNGase F enzyme in the presence of <sup>18</sup>O water. Any peptide with an occupied N-glycan site will gain 3Da from the <sup>18</sup>O incorporated by the enzyme. The relative occupancy proportion is obtained by analysing the digested sample using C18-LC-MS/MS or MALDI-TOF-MS/ MS (see Figure 1).

Proteolysis	Glycan Release	Analysis		Report Contents
Reduction/alkylation and protease digestion	PNGase F + <sup>18</sup> O Water LZ-rPNGaseF-kit E-PNG01 E-PNG01-200 E-rPNG01	MALDI-TOF-MS/MS or C18-LC-MS/MS	1. (	C18-LC-MS/MS or MALDI- TOF-MS/MS spectra for the <sup>18</sup> O deglycosylated peptide sample
Standa	2. (	C18-LC-MS/MS or MALDI- TOF-MS/MS spectra for		
KV.	3. 4.	Proportion of N-glycan occupancy at each glycosylation site Summary of findings		

Note that the analytical protocol must be adapted to each sample based on its amino acid sequence and buffer formulation.



**Figure 1.** LC-ESI-MS spectra showing the mass different between occupied and unoccupied glycopeptide after PNGase F digestion in presence of <sup>18</sup>O water.

#### Used for:

- Quality control: batch-to-batch consistency
- Biosimilars: comparability studies

Our team has years of experience in glycoprofiling. They will choose the best parameters for your sample and run it alongside the appropriate **Ludger positive and negative controls**, and system suitability standards.

#### Type of sample sources:

- Biopharmaceuticals such as mAbs and glycoprotein hormones (e.g. follicle stimulating hormone (FSH) and erythropoietin (EPO), Fc fusion proteins, vaccines)
- Cultured cells, clinical tissues, or fluids (e.g., SARS-CoV-2 infected cell lines and COVID-19 patient plasma and tissue samples).

Given its complexity, this type of analysis is offered at Ludger as a Level 3 or advanced analytical module.

If further information on the N-glycan composition at any specific glycosylation site is required, we recommend using Ludger's **Level 3 site-specific glycosylation analysis**.

## LudgerTag™ Glycopeptide Labelling & Enrichment Kit

2-hour sample preparation

V-Tag Glycopeptide Analysis Kit integrates with your **peptide mapping** workflow. It is used to **monitor batch-to-batch consistency** during the manufacturing of monoclonal antibodies (mAbs). Also, the kit complies with ICH Q2(R1) guidelines and can be used in comparability studies to **validate the biosimilarity** of new therapeutics.

LT-VTAG-24 allows the preparation of samples in **only 2 hours** starting with as little as **10µg** of mAb glycoprotein.

Proteolysis	Labelling	Clean Up	Analysis	Outcome
Tripsin Digest (1 hr)	Glycopeptide Labelling And Enrichment Kit <b>LT-VTAG-24</b> (1 hr)	LudgerClean A cartridges <b>LC-A-24*</b> (1 hr)	UHPLC and MALDI-MS	Reliable mAb glycoprofiling Glycopeptide mapping

\* Glycopeptide enrichment cartridges (LC-A-24) can be purchased both individually and as part of the LT-VTAG-24 kit.

For more information about these products, please visit **our website** or **contact us**.

# Find your Local Ludger Distributor

We offer direct worldwide delivery of our products to your doorstep.

Should you wish to source our products locally, we have a global network of trusted and authorised distributors who will assist you in procuring our products. (Check our updated contact page for the **list of distributors** in different territories listed alphabetically).



If you have any technical or logistics questions? **Contact us directly.** Our team of experts are here to help you find the perfect glycan analysis solution for your specific needs.

Join our Glycotechnology News Service

